CELZ buys 4M BioDefense shares for $200K cash plus 1M CELZ shares, lifting stake to 80%

CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.

Creative Medical Technology Holdings acquired 4,000,000 BioDefense, Inc. shares from Creative Acquisition Corp. for $200,000 cash plus 1,000,000 CELZ common shares; closing Sept. 24, 2026.
After the deal CELZ holds 16,000,000 BioDefense shares (80% of outstanding), with seller CAC retaining 4,000,000 shares (20%).
CAC is controlled by CELZ President/CEO Timothy Warbington, who is Chairman/CEO of CAC and indirectly owns all of its stock, making this a related-party transaction.
The 1,000,000 CELZ shares were issued in a private placement under Section 4(a)(2) of the Securities Act and are unregistered, with transfer restrictions noted in the agreement.
Agreement executed by Warbington for CAC and CFO Donald Dickerson for CELZ; governed by Nevada law, with a Stock Power transferring the 4M BioDefense shares.

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.